Olix wins Australian approval for Phase 2a trial of OLX301A
AI Summary- Olix received Australian approval for an OLX301A Phase 2a clinical trial.
- OLX301A is being developed for age-related macular degeneration.
- Olix disclosed the approval on the 30th, according to the company.